Pharmacoeconomic Evaluation of Linezolid Versus Teicoplanin in Bacteremia by Gram-Positive Microorganisms*

Author： Grau Santiago   Antonio Javier Mateu-de   Soto Javier   Marín-Casino Mónica   Salas Esther  

Publisher： Springer Publishing Company

ISSN： 0928-1231

Source： Pharmacy World and Science, Vol.27, Iss.6, 2005-12, pp. : 459-464

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Linezolid: A Pharmacoeconomic Review of its Use in Serious Gram-Positive Infections

By Plosker Greg L.   Figgitt David P.  

PharmacoEconomics, Vol. 23, Iss. 9, 2005-01 ,pp. : 945-964

Adis International

Access to resources Recommend Favorite

Linezolid: In Infants and Children with Severe Gram-Positive Infections

By Lyseng-Williamson K.A.   Goa K.L.  

Pediatric Drugs, Vol. 5, Iss. 6, 2003-01 ,pp. : 419-429

Adis International

Access to resources Recommend Favorite

Linezolid - meeting the challenge of Gram-positive resistance

By  

Inpharma, Vol. 1, Iss. 1225, 2000-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

Benefit-Risk Assessment of Linezolid for Serious Gram-Positive Bacterial Infections

By Falagas Matthew E.   Vardakas Konstantinos Z.  

Drug Safety, Vol. 31, Iss. 9, 2008-01 ,pp. : 753-768

Adis International

Access to resources Recommend Favorite

Linezolid: A Review of its Use in the Management of Serious Gram-Positive Infections

By Perry C.M.   Jarvis B.  

Drugs, Vol. 61, Iss. 4, 2001-01 ,pp. : 525-551

Adis International

Access to resources Recommend Favorite